Medizinische Klinik und Poliklinik I, University Hospital Dresden, Dresden, Germany.
DKMS Clinical Trials Unit, Dresden, Germany.
Front Immunol. 2021 Jan 19;11:584520. doi: 10.3389/fimmu.2020.584520. eCollection 2020.
Results from registry studies suggest that harnessing Natural Killer (NK) cell reactivity mediated through Killer cell Immunoglobulin-like Receptors (KIR) could reduce the risk of relapse after allogeneic Hematopoietic Cell Transplantation (HCT). Several competing models have been developed to classify donors as KIR-advantageous or disadvantageous. Basically, these models differ by grouping donors based on distinct KIR-KIR-ligand combinations or by haplotype motif assignment. This study aimed to validate different models for unrelated donor selection for patients with Myelodysplatic Syndromes (MDS) or secondary Acute Myeloid Leukemia (sAML). In a joint retrospective study of the European Society for Blood and Marrow Transplantation (EBMT) and the Center for International Blood and Marrow Transplant Research (CIBMTR) registry data from 1704 patients with secondary AML or MDS were analysed. The cohort consisted mainly of older patients (median age 61 years) with high risk disease who had received chemotherapy-based reduced intensity conditioning and anti-thymocyte globulin prior to allogeneic HCT from well-matched unrelated stem cell donors. The impact of the predictors on Overall Survival (OS) and relapse incidence was tested in Cox regression models adjusted for patient age, a modified disease risk index, performance status, donor age, HLA-match, sex-match, CMV-match, conditioning intensity, type of T-cell depletion and graft type. genes were typed using high-resolution amplicon-based next generation sequencing. In univariable and multivariable analyses none of the models predicted OS and the risk of relapse consistently. Our results do not support the hypothesis that optimizing NK-mediated alloreactivity is possible by KIR-genotype informed selection of HLA-matched unrelated donors. However, in the context of allogeneic transplantation, NK-cell biology is complex and only partly understood. KIR-genes are highly diverse and current assignment of haplotype motifs based on the presence or absence of selected KIR genes is over-simplistic. As a consequence, further research is highly warranted and should integrate cutting edge knowledge on KIR genetics, and NK-cell biology into future studies focused on homogeneous groups of patients and treatment modalities.
研究结果表明,利用通过杀伤细胞免疫球蛋白样受体(KIR)介导的自然杀伤(NK)细胞反应可以降低异基因造血细胞移植(HCT)后复发的风险。已经开发了几种竞争模型来将供体分类为 KIR 有利或不利。基本上,这些模型通过基于不同的 KIR-KIR-配体组合或通过单倍型基序分配来对供体进行分组而有所不同。本研究旨在为骨髓增生异常综合征(MDS)或继发性急性髓系白血病(sAML)患者验证用于选择无关供体的不同模型。在对欧洲血液和骨髓移植学会(EBMT)和国际血液和骨髓移植研究中心(CIBMTR)注册数据的联合回顾性研究中,对 1704 名患有继发性 AML 或 MDS 的患者进行了分析。该队列主要由接受基于化疗的低强度预处理和异基因 HCT 前接受抗胸腺细胞球蛋白的老年患者(中位年龄 61 岁)组成,这些患者患有高危疾病,并且来自匹配良好的无关干细胞供体。在调整了患者年龄、改良疾病风险指数、表现状态、供体年龄、HLA 匹配、性别匹配、CMV 匹配、预处理强度、T 细胞耗竭类型和移植物类型的 Cox 回归模型中,测试了预测因素对总生存(OS)和复发发生率的影响。使用高分辨率扩增子基于下一代测序对基因进行了分型。在单变量和多变量分析中,没有一种模型可以一致地预测 OS 和复发风险。我们的结果不支持通过 KIR 基因型告知选择 HLA 匹配的无关供体来优化 NK 介导的同种异体反应的假设。然而,在同种异体移植的背景下,NK 细胞生物学是复杂的,并且仅部分得到理解。KIR 基因高度多样化,目前基于存在或不存在选定的 KIR 基因来分配单倍型基序过于简单化。因此,强烈需要进一步研究,并应将 KIR 遗传学和 NK 细胞生物学的最新知识纳入针对同质患者群体和治疗方式的未来研究中。